FR3096579B1 - composition pour la protection et la reparation de la barriere hematoencephalique (BHE) - Google Patents

composition pour la protection et la reparation de la barriere hematoencephalique (BHE) Download PDF

Info

Publication number
FR3096579B1
FR3096579B1 FR1905566A FR1905566A FR3096579B1 FR 3096579 B1 FR3096579 B1 FR 3096579B1 FR 1905566 A FR1905566 A FR 1905566A FR 1905566 A FR1905566 A FR 1905566A FR 3096579 B1 FR3096579 B1 FR 3096579B1
Authority
FR
France
Prior art keywords
repair
protection
composition
bbb
hematoencephalic barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1905566A
Other languages
English (en)
Other versions
FR3096579A1 (fr
Inventor
Myriam Bernaudin
Omar Touzani
Jérôme Toutain
Yacine Khelif
Denis Barritault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organes Tissus Regeneration Reparation Remplacement
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
Original Assignee
Organes Tissus Regeneration Reparation Remplacement
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1905566A priority Critical patent/FR3096579B1/fr
Application filed by Organes Tissus Regeneration Reparation Remplacement, Centre National de la Recherche Scientifique CNRS, Universite de Caen Normandie filed Critical Organes Tissus Regeneration Reparation Remplacement
Priority to EP20721621.9A priority patent/EP3976060A1/fr
Priority to BR112021023737A priority patent/BR112021023737A2/pt
Priority to AU2020284406A priority patent/AU2020284406A1/en
Priority to US17/595,818 priority patent/US20220152089A1/en
Priority to KR1020217042420A priority patent/KR20220042310A/ko
Priority to CN202080047142.7A priority patent/CN114206354B/zh
Priority to PCT/EP2020/062081 priority patent/WO2020239356A1/fr
Priority to CA3141923A priority patent/CA3141923A1/fr
Priority to JP2021570515A priority patent/JP2022534278A/ja
Publication of FR3096579A1 publication Critical patent/FR3096579A1/fr
Application granted granted Critical
Publication of FR3096579B1 publication Critical patent/FR3096579B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à une composition pharmaceutique pour son application comme médicament, en particulier pour son utilisation pour la protection de la barrière hématoencéphalique et/ou la réparation et/ou la restauration de la barrière hématoencéphalique. La présente invention trouve une application notamment dans les domaines thérapeutique, pharmaceutiques et vétérinaires. Figure abrégé [Fig. 3]
FR1905566A 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE) Active FR3096579B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1905566A FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
CA3141923A CA3141923A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)
AU2020284406A AU2020284406A1 (en) 2019-05-27 2020-04-30 Composition for the protection and repair of the blood brain barrier
US17/595,818 US20220152089A1 (en) 2019-05-27 2020-04-30 Composition for the protection and repair of the blood brain barrier
KR1020217042420A KR20220042310A (ko) 2019-05-27 2020-04-30 혈액-뇌 장벽(ｂｂｂ)의 보호 및 복구용 조성물
CN202080047142.7A CN114206354B (zh) 2019-05-27 2020-04-30 用于保护和修复血脑屏障(bbb)的组合物
EP20721621.9A EP3976060A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)
BR112021023737A BR112021023737A2 (pt) 2019-05-27 2020-04-30 Composição farmacêutica e uso
JP2021570515A JP2022534278A (ja) 2019-05-27 2020-04-30 血液脳関門（ｂｂｂ）の保護及び修復のための組成物
PCT/EP2020/062081 WO2020239356A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905566 2019-05-27
FR1905566A FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)

Publications (2)

Publication Number Publication Date
FR3096579A1 FR3096579A1 (fr) 2020-12-04
FR3096579B1 true FR3096579B1 (fr) 2023-05-05

Family

ID=68138337

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1905566A Active FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)

Country Status (10)

Country Link
US (1) US20220152089A1 (fr)
EP (1) EP3976060A1 (fr)
JP (1) JP2022534278A (fr)
KR (1) KR20220042310A (fr)
CN (1) CN114206354B (fr)
AU (1) AU2020284406A1 (fr)
BR (1) BR112021023737A2 (fr)
CA (1) CA3141923A1 (fr)
FR (1) FR3096579B1 (fr)
WO (1) WO2020239356A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024119112A1 (fr) * 2022-12-01 2024-06-06 Stream Biomedical, Inc. Utilisation de perlécan et de fragments de celle-ci pour traiter une rupture de la barrière hémato-encéphalique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
FR2718025B1 (fr) * 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux.
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
WO2001051003A2 (fr) * 2000-01-10 2001-07-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Utilisation de conjugues de lipides dans le traitement de maladies
FR2832708B1 (fr) 2001-11-29 2004-02-13 Organes Tissus Regeneration Re Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires
EP2260853B1 (fr) 2003-10-28 2015-10-21 Organes Tissus Régénération Réparation Remplacement Polymères biocompatibles pour une composition médicale
US20090062208A1 (en) 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
CN101632728B (zh) 2008-07-21 2013-08-07 河北以岭医药研究院有限公司 一种中药组合物在制备保护血脑屏障的药物中的应用
EP3097928A1 (fr) * 2015-05-28 2016-11-30 Organes Tissus Régénération Réparation Remplacement Composition pour le traitement des lesions cerebrales
EP3097922A1 (fr) * 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN105148276B (zh) 2015-09-22 2018-11-20 深圳市第二人民医院 抑制Claudin-5降解阻止缺血性血脑屏障损伤的保护剂
JP7106340B2 (ja) 2017-05-12 2022-07-26 花王株式会社 血液脳関門保護剤

Also Published As

Publication number Publication date
KR20220042310A (ko) 2022-04-05
AU2020284406A1 (en) 2022-01-06
FR3096579A1 (fr) 2020-12-04
US20220152089A1 (en) 2022-05-19
CA3141923A1 (fr) 2020-12-03
EP3976060A1 (fr) 2022-04-06
JP2022534278A (ja) 2022-07-28
WO2020239356A1 (fr) 2020-12-03
CN114206354B (zh) 2023-12-29
BR112021023737A2 (pt) 2022-02-01
CN114206354A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
Gomes et al. Chlorhexidine in endodontics
Mollashahi et al. Evaluation of cytotoxic effects of various endodontic irrigation solutions on the survival of stem cell of human apical papilla
Victorino et al. The effects of chlorhexidine and ethanol on push-out bond strength of fiber posts
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
MA37809A1 (fr) Administration de médicament biodégradable pour compositions hydrophobes
Sabatini et al. Matrix metalloproteinase inhibitory properties of benzalkonium chloride stabilizes adhesive interfaces
Pithon et al. Effect of 10% papain gel on enamel deproteinization before bonding procedure
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
Shafiei et al. Effect of carbodiimide on bonding durability of adhesive-cemented fiber posts in root canals
BR0207910A (pt) HidantÈnios e sua utilização no tratamento do diabetes
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MD3830120T2 (ro) Noi proteine de fuziune specifice pentru CD137 și PD-L1
BR9808427A (pt) Produto, processo de preparação e utilização do mesmo e composição farmacêutica
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
BR0111678A (pt) Composições medicinais contendo derivados de propenona
FR3096579B1 (fr) composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
Hadrous et al. Evaluation of shear bond strength of orthodontic molar tubes bonded using hydrophilic primers: an in vitro study
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
BR0009674A (pt) Composto, droga, e, uso de composto
MA27474A1 (fr) Vaccin
FR2997405B1 (fr) Utilisation d'une silice precipitee contenant du titane et d'un agent de couplage specifique dans une composition d'elastomere(s)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201204

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6